Literature DB >> 1541694

Increased numbers of pulmonary megakaryocytes in patients with arterial pulmonary tumour embolism and with lung metastases seen at necropsy.

F A Soares1.   

Abstract

AIMS: To compare the number of pulmonary megakaryocytes in patients with local malignant disease without metastases with the numbers in patients with pulmonary tumour emboli without lung metastases and with those with pulmonary metastases.
METHODS: The prevalence of pulmonary megakaryocytes was studied in 40 necropsies divided into four groups of 10 cases each: normal lungs (I); localised malignancies (II); pulmonary tumour embolism without lung metastases (III); pulmonary tumour embolism and lung metastases (IV). Five fragments (one of each pulmonary lobe) of tissue lung were collected, embedded in paraffin wax, sectioned, and stained by an immunohistochemical method to detect factor VIII related antigen. The number of megakaryocytes was evaluated in 500 high power fields/case.
RESULTS: No differences were observed between groups I and II or between groups III and IV, but there was a 3.5-fold increase in the number of megakaryocytes in the groups with pulmonary tumour embolism or lung metastases compared with those with local neoplasms or normal lungs.
CONCLUSIONS: An increased number of pulmonary megakaryocytes correlated with the presence of tumour cells in the microcirculation of the lungs or parenchymal metastases, but not with local malignancies without lung disease. The permanent siting of tumour emboli may stimulate megakaryocytes to migrate to the lungs, and may increase the release of platelets into the pulmonary circulation.

Entities:  

Mesh:

Year:  1992        PMID: 1541694      PMCID: PMC495657          DOI: 10.1136/jcp.45.2.140

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  QUANTITATIVE OBSERVATIONS OF CIRCULATING MEGAKARYOCYTES IN THE BLOOD OF PATIENTS WITH CANCER.

Authors:  R HUME; J T WEST; R A MALMGREN; E A CHU
Journal:  N Engl J Med       Date:  1964-01-16       Impact factor: 91.245

2.  Evaluation of pulmonary megakaryocytes.

Authors:  J G SHARNOFF; E S KIM
Journal:  AMA Arch Pathol       Date:  1958-08

3.  The incidence, distribution and significance of Megakaryocytes in normal and diseased human tissues.

Authors:  E B SMITH; J BUTCHER
Journal:  Blood       Date:  1952-02       Impact factor: 22.113

Review 4.  Interactions of cancer cells with the microvasculature during metastasis.

Authors:  L Weiss; F W Orr; K V Honn
Journal:  FASEB J       Date:  1988-01       Impact factor: 5.191

5.  The pulmonary vessels as a filter for circulating megakaryocytes in rats.

Authors:  N T Pedersen
Journal:  Scand J Haematol       Date:  1974

6.  Circulating megakaryocytes and platelet release in the lung.

Authors:  R M Kaufman; R Airo; S Pollack; W H Crosby
Journal:  Blood       Date:  1965-12       Impact factor: 22.113

7.  Megakaryocytes in pulmonary blood vessels. I. Incidence at autopsy, clinicopathological relations especially to disseminated intravascular coagulation.

Authors:  K Aabo; K B Hansen
Journal:  Acta Pathol Microbiol Scand A       Date:  1978-07

8.  Distribution of intrapulmonary megakaryocytes.

Authors:  K Bendix-Hansen; K Aabo
Journal:  Acta Pathol Microbiol Scand A       Date:  1981-03

9.  Pulmonary megakaryocytes: "missing link" between cardiovascular and respiratory disease?

Authors:  G K Sharma; I C Talbot
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

10.  Occurrence of megakaryocytes in various vessels and their retention in the pulmonary capillaries in man.

Authors:  N T Pedersen
Journal:  Scand J Haematol       Date:  1978-11
  10 in total
  2 in total

Review 1.  Megakaryocytes, malignancy and bone marrow vascular niches.

Authors:  B Psaila; D Lyden; I Roberts
Journal:  J Thromb Haemost       Date:  2012-02       Impact factor: 5.824

Review 2.  Megakaryocytes in Bone Metastasis: Protection or Progression?

Authors:  Paola Maroni
Journal:  Cells       Date:  2019-02-08       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.